The CEO driving change at Curia
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Philip Macnabb, Chief Executive Officer at Curia.
Your host, Raman Sehgal, speaks with Phil about the pharmaceutical and biotechnology supply chain, covering:
Over 25 years of working with private equity — and why PE is ultimately about building sustainable value.
The common threads he looks for as a CEO of any new organisation, and why employees often know the answer first.
Navigating the COVID comedown at Curia, making major network changes, and refocusing on biotech clients.
Why CDMOs are really selling trust as the service, not just manufacturing — and how that plays into customer intimacy and reputation.
Betting on the trend toward small batch sizes and personalised medicines in biotech and pharma.
Phil leads Curia in pursuit of its mission to improve patients’ lives, applying end-to-end capabilities and deep scientific expertise to advance customers from idea to impact.
He brings more than 20 years of private-equity leadership experience to Curia, including the last decade in healthcare. Most recently, he served as Chief Executive Officer at Epsilon Global, a company he co-founded. In addition to his healthcare experience, he has held senior positions in technology, distribution, and consumer products. Phil has a proven track record of sharpening companies’ core value proposition, enhancing the customer experience, and building organisations with real, lasting value.
Phil earned an MBA from the University of Chicago and a BS in Business Administration from Purdue University.
Molecule to Market is sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!
Ireland